The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2 diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully understood how liraglutide induces weight loss or to what degree liraglutide acts directly in the brain. Here, we determined that liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus. Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. Moreover, labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus. GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r(-/-) mice. In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART). Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling. Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1R and GIP-R have been identified in brain regions involved in the regulation of appetite, satiety, food/energy intake and energy expenditure, which is consistent with the significant impact on body weight observed with incretin therapy.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies have demonstrated that the principal sites of action accessible to these drugs are GLP-1R neurons in circumventricular organs, particularly the AP and ME, and those in immediately adjacent regions—the NTS and arcuate nucleus of the hypothalamus (16, 51, 63‐66).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The individual necessity of distinct GLP-1R neuron populations for the anorectic and weight loss effects of GLP-1RAs has now been claimed by multiple studies using various loss-of-function approaches in rodents (47, 50‐54, 69).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies also indicate that tanycytes, specialized glial cells within the CNS, may facilitate the transportation of peripheral GLP-1RAs, such as semaglutide, into the CNS, bypassing the blood-brain barrier to access appetite-regulating hypothalamic regions such as the arcuate nucleus (60, 61).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [61]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent mechanistic studies, primarily conducted in rodents, have identified a number of sites of direct action putatively mediating the effects of GLP-1-based AOMs on eating and body weight, including the area postrema and nucleus tractus solitarius (47‐49), locus coeruleus (50), hypothalamic arcuate (51, 52) and dorsomedial nuclei (53), and the lateral septal nucleus (54).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 9×
“In 7 of 7 cells (from 5 mice), GLP-1(7-36)amide failed to change the current in the presence of bicuculline (Figure 2, D and F), demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.”
InfluentialDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“Physiologically, GLP-1 released from endocrine cells lining the gut acts peripherally (13, 42).”
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 4×
“Given the well-known role of NTS-produced GLP-1 in appetite regulation, it is tempting to speculate that peripheral administration of GLP-1 or analogs activates NTS GLP-1–positive neurons that in turn reduce appetite (22, 23).”
InfluentialObesity is associated with hypothalamic injury in rodents and humans.
Thaler, J. P., Yi, C.-X., Schur, E. A., Guyenet, S. J., Hwang, B. H., Dietrich, M. O., Zhao, X., Sarruf, D. A., Izgur, V., Maravilla, K. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59660 · Cited by 1,857
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“…analogs, like exenatide and lixisenatide, display a marked reduction of GE, which may contribute to short-term effects on food intake, while liraglutide and exenatide, formulated for slow release, have only a minor effect on GE, which then cannot be the mediator of the body weight effects (16, 17).”
Hypothalamic CART is a new anorectic peptide regulated by leptin
Kristensen, P., Judge, M. E., Thim, L., Ribel, U., Christjansen, K. N., Wulff, B. S., Clausen, J. T., Jensen, P. B., Madsen, O. D., Vrang, N., et al. (1998) · Nature · doi:10.1038/29993 · Cited by 1,282 · cited 1×
“…access to the brain and how they may affect the key neuronal pathways that regulate energy balance, such as the neuropeptide Y/agouti-related peptide (NPY/ AgRP) and proopiomelanocortin/cocaine-and amphetamine-regulated transcript (POMC/CART) neurons located in the arcuate nucleus (ARC) (7–11).”
Self-citationAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“Liraglutide dose dependently lowers body weight by reducing energy intake via an overall appetite reduction (31, 32).”
NPY/AgRP Neurons Are Essential for Feeding in Adult Mice but Can Be Ablated in Neonates
Luquet, S., Perez, F. A., Hnasko, T. S., & Palmiter, R. D. (2005) · Science · doi:10.1126/science.1115524 · Cited by 1,125
Research works printed but not linked: 1
- Astrup A, Rossner S, Van Gaal L. Effects of lirag- lutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616. · DOI · Paper page
Cited by
Items 201–300 of 958
The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution
Zhao, L., Zhu, C., Lu, M., Chen, C., Nie, X., Abudukerimu, B., Zhang, K., Ning, Z., Chen, Y., Cheng, J., et al. (2019) · Journal of Endocrinology · doi:10.1530/joe-18-0374 · Cited by 67
Clinical Impact of Liraglutide as a Treatment of Obesity
Alruwaili, H., Dehestani, B., & le Roux, C. W. (2021) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s276085 · Cited by 93
“Liraglutide directly stimulates POMC neurons and inhibits neuropeptide-Y (NPY) and Agouti-related peptide (AgRP) neurons in the arcuate nucleus resulting in a reduction in hunger and increases in fullness.(30) These actions can also be associated with effects on other brain areas such as the mesolimbic system resultin…”
BackgroundMechanisms of surgical control of type 2 diabetes: GLP-1 is key factor
Holst, J. J., & Madsbad, S. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.02.033 · Cited by 67
“[13] Secher A, Jelsing J, Baquero AF, et al.”
BackgroundIntestinal GLP-1 and satiation: from man to rodents and back
Steinert, R. E., Beglinger, C., & Langhans, W. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.172 · Cited by 78
Elliott, J. A., Docherty, N. G., Eckhardt, H., Doyle, S. L., Guinan, E. M., Ravi, N., Reynolds, J. V., & le Roux, C. W. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001918 · Cited by 76
Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
“…[36]. activate neurons containing pro-opiomelanocortin/cocaine-and amphetamine-stimulated transcription (POMC + /CART + ), resulting in satiety [35 can concurrently stimulate local inhibitory GABA neurons, which indirectly It is thought that vagal innervation is involved in the GLP-1…”
BackgroundWhole-brain activation signatures of weight-lowering drugs
Hansen, H. H., Perens, J., Roostalu, U., Skytte, J. L., Salinas, C. G., Barkholt, P., Thorbek, D. D., Rigbolt, K. T. G., Vrang, N., Jelsing, J., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101171 · Cited by 66
“In the ARH, GLP-1 receptor agonist induced inhibition of food intake is mediated by direct activation of proopiomelanocortin/cocaine-and amphetamine-regulated transcript (POMC/CART) neurons and indirect inhibition of neuropeptide Y/agouti-related peptide (NPY/AgRP) neurons [48,49].”
BackgroundSelf-citationEndogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption
ten Kulve, J. S., Veltman, D. J., van Bloemendaal, L., Groot, P. F. C., Ruhé, H. G., Barkhof, F., Diamant, M., & Ijzerman, R. G. (2016) · Journal of Endocrinology · doi:10.1530/joe-15-0461 · Cited by 66
Vosoughi, K., Salman Roghani, R., & Camilleri, M. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100456 · Cited by 65
An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
Lin, C.-H., Shao, L., Zhang, Y.-M., Tu, Y.-J., Zhang, Y., Tomlinson, B., Chan, P., & Liu, Z. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1695779 · Cited by 65
Christensen, M., Sparre‐Ulrich, A. H., Hartmann, B., Grevstad, U., ROSENKILDE, M. M., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.136 · Cited by 71
Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 65
“Many of the studies assessing peptide transport across the BBB do not actually report the detection of intact peptide; rather, they quantify radioactivity or fluorescence, which may represent intact or partially cleaved peptide.”
BackgroundMethodInfluentialLiraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
Overgaard, R. V., Petri, K. C., Jacobsen, L. V., & Jensen, C. B. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0410-7 · Cited by 64
“The mechanism for liraglutidemediated weight loss has been shown to involve an increase in hypothalamic satiety signals coupled with a decrease in appetite-stimulating signals, resulting in reduced energy intake [7, 8].”
The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
Hayes, M. R., Borner, T., & De Jonghe, B. C. (2021) · Diabetes · doi:10.2337/dbi21-0004 · Cited by 64
The role of astrocytes in the hypothalamic response and adaptation to metabolic signals
Chowen, J. A., Argente-Arizón, P., Freire-Regatillo, A., Frago, L. M., Horvath, T. L., & Argente, J. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.001 · Cited by 64
Translating biased signaling in the ghrelin receptor system into differential in vivo functions
Mende, F., Hundahl, C., Plouffe, B., Skov, L. J., Sivertsen, B., Madsen, A. N., Lückmann, M., Diep, T. A., Offermanns, S., Frimurer, T. M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1804003115 · Cited by 65
“However, nausea is a common adverse effect in many patients, sometimes leading to discontinuation of the treatment (33, 34).”
BackgroundCentral GLP-1 receptors: Novel molecular targets for cocaine use disorder
Hernandez, N. S., & Schmidt, H. D. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.03.026 · Cited by 63
“With regard to energy homeostasis, GLP-1 receptor agonists reduce food intake, in part, by activating central GLP-1 receptors [104, 107, 108].”
BackgroundGlucagon-like peptide-1 regulates brown adipose tissue thermogenesis via the gut-brain axis in rats
Krieger, J.-P., Santos da Conceição, E. P., Sanchez-Watts, G., Arnold, M., Pettersen, K. G., Mohammed, M., Modica, S., Lossel, P., Morrison, S. F., Madden, C. J., et al. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00068.2018 · Cited by 63
Guerrero-Hreins, E., Goldstone, A. P., Brown, R. M., & Sumithran, P. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110303 · Cited by 62
Colvin, K. J., Killen, H. S., Kanter, M. J., Halperin, M. C., Engel, L., & Currie, P. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249710 · Cited by 61
“Further, we observed decreased operant responding for sucrose pellets when Ex-4 was administered into the ArcN or PVN [21,61].”
BackgroundHansen, H. H., Fabricius, K., Barkholt, P., Kongsbak-Wismann, P., Schlumberger, C., Jelsing, J., Terwel, D., Termont, A., Pyke, C., Knudsen, L. B., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158205 · Cited by 62
“It should be noted that liraglutide enters the murine brain upon systemic administration [4].”
BackgroundSelf-citationMarlet, I. R., Ölmestig, J. N. E., Vilsbøll, T., Rungby, J., & Kruuse, C. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12974 · Cited by 61
Huang, R., Ding, X., Fu, H., & Cai, Q. (2019) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.06.022 · Cited by 74
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Geloneze, B., de Lima-Júnior, J. C., & Velloso, L. A. (2017) · Drugs · doi:10.1007/s40265-017-0706-4 · Cited by 60
“Stimulatory effect on anorexigenic neurons and inhibitory effect on orexigenic neurons : Satiety and consequent weight loss [26]”
BackgroundFerrari, F., Moretti, A., & Villa, R. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108277 · Cited by 59
Aoun, L., Almardini, S., Saliba, F., Haddadin, F., Mourad, O., Jdaidani, J., Morcos, Z., Al Saidi, I., Bou Sanayeh, E., Saliba, S., et al. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100333 · Cited by 56
“The efficacy of GLP-1RAs is further supported by their impact on hunger and satiety regulation in the hypothalamus [19].”
BackgroundThe GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
Crane, J., & McGowan, B. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315620180 · Cited by 59
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“In rodent models, the majority of POMC/CART neurons have GLP-1 receptors, predominantly in the arcuate nucleus of the hypothalamus [118].”
Effects of liraglutide in hypothalamic arcuate nucleus of obese mice
Barreto‐Vianna, A. R. C., Aguila, M. B., & Mandarim‐de‐Lacerda, C. A. (2016) · Obesity · doi:10.1002/oby.21387 · Cited by 58
“CART-positive cells in the ARC nucleus were positive for liraglutide after the peripheral administration of fluorescently labeled liraglutide, indicating that the decrease in BM caused by peripheral administration of liraglutide appears to be consistent with the direct activation of POMC/CART neurons in the ARC, with…”
MethodResultHeppner, K. M., Baquero, A. F., Bennett, C. M., Lindsley, S. R., Kirigiti, M. A., Bennett, B., Bosch, M. A., Mercer, A. J., Rønnekleiv, O. K., True, C., et al. (2017) · eneuro · doi:10.1523/eneuro.0198-16.2016 · Cited by 57
“Activation of GLP-1R signaling directly stimulates ARC POMC neurons and indirectly inhibits ARC NPY neurons, which are thought to be important mechanisms whereby GLP-1R agonists mediate a reduction in body weight (Secher et al., 2014).”
BackgroundSelf-citationMolecular Connectomics Reveals a Glucagon-Like Peptide 1 Sensitive Neural Circuit for Satiety
Webster, A. N., Becker, J. J., Li, C., Schwalbe, D. C., Kerspern, D., Karolczak, E. O., Bundon, C., Onoharigho, R. A., Crook, M., Jalil, M., et al. (2023) · doi:10.1101/2023.10.31.564990 · Cited by 56
Lucey, M., Pickford, P., Bitsi, S., Minnion, J., Ungewiss, J., Schoeneberg, K., Rutter, G. A., Bloom, S. R., Tomas, A., & Jones, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.100991 · Cited by 55
Marrano, N., Biondi, G., Borrelli, A., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2021) · Biomolecules · doi:10.3390/biom11020286 · Cited by 56
Domingo, E., Marqués, P., Francisco, V., Piqueras, L., & Sanz, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107058 · Cited by 74
Molecular connectomics reveals a glucagon-like peptide 1-sensitive neural circuit for satiety
Webster, A. N., Becker, J. J., Li, C., Schwalbe, D. C., Kerspern, D., Karolczak, E. O., Bundon, C. B., Onoharigho, R. A., Crook, M., Jalil, M., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01168-8 · Cited by 55
“Fluorescently labelled liraglutide binds to Arc neurons after systemic administration 3 , probably due to its transport by tanycytes 9 , specialized ependymal cells along the third ventricle.”
InfluentialWest, J., Li, M., Wong, S., Le, G. H., Teopiz, K. M., Valentino, K., Dri, C. E., & McIntyre, R. S. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00724-y · Cited by 73
“Preclinical studies suggest that liraglutide interacts with circumventricular organs but was also found in the arcuate nucleus (ARC) and paraventricular nucleus (PVN), which is protected by the BBB and suggests other ways of transport other than passive diffusion [23].”
Thiebaud, N., Llewellyn‐Smith, I. J., Gribble, F., Reimann, F., Trapp, S., & Fadool, D. A. (2016) · The Journal of Physiology · doi:10.1113/jp272322 · Cited by 56
“Consistent with previous studies, GLP-1 analogues are internalized in neurons after binding to the receptor (Roed et al. 2014; Secher et al. 2014; Roed et al. 2015).”
MethodResultInventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
Decreased Hypothalamic Glucagon-Like Peptide-1 Receptor Expression in Type 2 Diabetes Patients
ten Kulve, J. S., van Bloemendaal, L., Balesar, R., IJzerman, R. G., Swaab, D. F., Diamant, M., la Fleur, S. E., & Alkemade, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3291 · Cited by 54
Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease
Hershon, K. S., Hirsch, B. R., & Odugbesan, O. (2019) · Clinical Diabetes · doi:10.2337/cd18-0040 · Cited by 67
“A study has shown that GLP-1 receptors are required to be present in the central nervous system, while another study showed that a small peptide GLP-1 receptor agonist can penetrate the brain, subsequently activating certain neurons to stimulate weight loss (84,85).”
BackgroundThe gut–brain axis in vertebrates: implications for food intake regulation
Blanco, A. M., Calo, J., & Soengas, J. L. (2021) · Journal of Experimental Biology · doi:10.1242/jeb.231571 · Cited by 63
Gut microbes and food reward: From the gut to the brain
d’Oplinter, A. D. W., Huwart, S. J. P., Cani, P. D., & Everard, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.947240 · Cited by 59
“Both central and peripheral GLP-1 agonists are able to inhibit NPY and AgRP neurons and activate POMC neurons thereby inducing its anorexigenic effects (Figure 1; Seo et al., 2008; Secher et al., 2014; He et al., 2019).”
BackgroundBettadapura, S., Dowling, K., Jablon, K., Al-Humadi, A. W., & le Roux, C. W. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01500-y · Cited by 55
“Liraglutide also directly stimulates proopiomelanocortin neurons, and this has been postulated to result in reduced hunger and appetitive behavior [50, 51].”
Douton, J. E., Horvath, N., Mills‐Huffnagle, S., Nyland, J. E., Hajnal, A., & Grigson, P. S. (2022) · Addiction Biology · doi:10.1111/adb.13117 · Cited by 54
“obtained during heroin self-administration testing, where the most robust effects of LIR treatment were observed during Hours 5 and 6, and previous research has shown that it takes at least 4 h for LIR to reach hypothalamic areas in the brain after iv administration.(39) Taken together, these findings suggest that LIR…”
Gerstenberg, M. K., Salinas, C. B. G., Rehfeld, J. F., Secher, A., Raun, K., & Wulff, B. S. (2018) · Neuropeptides · doi:10.1016/j.npep.2018.11.004 · Cited by 56
“, 2002) and in ARH through activation of POMC/CART neurons and a simultaneous indirect GABAergic inhibition of the AgRP/NPY neurons (Secher et al., 2014; Barsh & Schwartz, 2002).”
BackgroundSelf-citationMancini, M. C., & de Melo, M. E. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0242-0 · Cited by 54
“Farr et at. identified, by immunohistochemical analysis, the presence of GLP-1R in hypothalamic nuclei, medulla oblongata, area postrema and parietal cortex of humans brains [23].”
BackgroundInfluentialDalsgaard, N. B., Vilsbøll, T., & Knop, F. K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13128 · Cited by 54
Diagnosis, Background, and Treatment of Hypothalamic Damage in Craniopharyngioma
Erfurth, E.-M. (2020) · Neuroendocrinology · doi:10.1159/000509616 · Cited by 54
Holst, J. J., Albrechtsen, N. J. W., Rosenkilde, M. M., & Deacon, C. F. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180013 · Cited by 54
“In other studies, peripheral liraglutide injections have been found to induce c-fos activity (indicating activation) in cells of the area postrema (30, 383) and to access the area postrema and the arcuate nucleus .”
Brain control of energy homeostasis: implications for anti-obesity pharmacotherapy
Johansen, V. B. I., Petersen, J., Lund, J., Mathiesen, C. V., Fenselau, H., & Clemmensen, C. (2025) · Cell · doi:10.1016/j.cell.2025.06.010 · Cited by 53
Gutgesell, R. M., Khalil, A., Liśkiewicz, A., Maity‐Kumar, G., Novikoff, A., Grandl, G., Liśkiewicz, D., Coupland, C., Karaoglu, E., Akindehin, S., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01294-x · Cited by 62
“Relevant brain areas implicated in GLP-1 control of body weight and food intake include the the hypothalamic arcuate nucleus 57–59 and the hindbrain DVC 59,60 , hence the same brain regions that are targeted by long-acting GIPR agonists 15,20,21 .”
Ishøy, P. L., Fagerlund, B., Broberg, B. V., Bak, N., Knop, F. K., Glenthoj, B. Y., & Ebdrup, B. H. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12711 · Cited by 59
“Preclinical studies in mice (43) and in primates (44) have shown that peripherally administered liraglutide can be detected in brain areas involved in Table 2.”
BackgroundChen, X.-Y., Chen, L., Yang, W., & Xie, A.-M. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.793004 · Cited by 52
Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52
Hakon, J., Ruscher, K., Romner, B., & Tomasevic, G. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120074 · Cited by 52
“This dose, however, has been used previously in several rodent experiments [72,73].”
BackgroundFu, Z., Gong, L., Liu, J., Wu, J., Barrett, E. J., Aylor, K. W., & Liu, Z. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00555 · Cited by 50
Yeh, T.-L., Tsai, M.-C., Tsai, W.-H., Tu, Y.-K., & Chien, K.-L. (2023) · PLOS ONE · doi:10.1371/journal.pone.0278685 · Cited by 50
Gut Microbiota Mediates Lactobacillus rhamnosus GG Alleviation of Deoxynivalenol-Induced Anorexia
Bai, Y., Meng, Q., Wang, C., Ma, K., Li, J., Li, J., & Shan, A. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c08076 · Cited by 57
Gut Microbiome Regulation of Gut Hormone Secretion
Chao, J. L., Coleman, R. A., Keating, D. J., & Martin, A. M. (2025) · Endocrinology · doi:10.1210/endocr/bqaf004 · Cited by 64
Is the Brain a Key Player in Glucose Regulation and Development of Type 2 Diabetes?
Lundqvist, M., Almby, K. E., Abrahamsson, N., & Eriksson, J. W. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00457 · Cited by 60
Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss
Liberini, C. G., Koch-Laskowski, K., Shaulson, E., McGrath, L. E., Lipsky, R. K., Lhamo, R., Ghidewon, M., Ling, T., Stein, L. M., & Hayes, M. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-44591-8 · Cited by 50
Potential gut–brain mechanisms behind adverse mental health outcomes of bariatric surgery
Brown, R. M., Guerrero-Hreins, E., Brown, W. A., le Roux, C. W., & Sumithran, P. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00520-2 · Cited by 49
Samms, R. J., Sloop, K. W., Gribble, F. M., Reimann, F., & Adriaenssens, A. E. (2021) · Diabetes · doi:10.2337/dbi21-0002 · Cited by 49
“GLP1RAs have been reported to access the CNS via CVOs, with limited permeability to brain regions that are fully protected by the blood-brain barrier (57,58).”
BackgroundThe Role of Glucagon-Like Peptide-1 in Energy Homeostasis
Salehi, M., & Purnell, J. Q. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0088 · Cited by 46
Borner, T., Tinsley, I. C., Doyle, R. P., Hayes, M. R., & De Jonghe, B. C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15647 · Cited by 49
Zaffina, I., Pelle, M. C., Armentaro, G., Giofrè, F., Cassano, V., Sciacqua, A., & Arturi, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1095753 · Cited by 56
“cocaine- and amphetamine-regulated transcripts (CART); liraglutide indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling (19).”
BackgroundThe regulation of function, growth and survival of GLP-1-producing L-cells
Kuhre, R. E., Holst, J. J., & Krizhanovskii, C. (2015) · Clinical Science · doi:10.1042/cs20150154 · Cited by 55
Chen, Z., Deng, X., Shi, C., Jing, H., Tian, Y., Zhong, J., Chen, G., Xu, Y., Luo, Y., & Zhu, Y. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178239 · Cited by 48
“Evidence supporting this concept is provided by the binding of fluorescently labeled liraglutide to neurons in the Arc and specific hypothalamic regions in mice (49).”
BackgroundHamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 96
Burmeister, M. A., Brown, J. D., Ayala, J. E., Stoffers, D. A., Sandoval, D. A., Seeley, R. J., & Ayala, J. E. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00113.2017 · Cited by 48
“Liraglutide [200 g/kg body wt sc bid (28)] or isotonic saline was administered for 14 days in chow- and HFD-fed mice, and body weight was measured daily as well as during a 7-day recovery period over which animals received no injection.”
MethodGlucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Mayfield, K., Siskind, D., Winckel, K., Russell, A. W., Kisely, S., Smith, G., & Hollingworth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625496 · Cited by 49
“In support of this, Lykkegaard et al. (2008) and Sharma et al. (2014) also found that liraglutide treatment (14 days and 21 days, respectively) in olanzapine-treated rats reversed or significantly reduced the metabolic abnormalities associated with long-term olanzapine treatment (including…”
BackgroundSmith, C., Patterson-Cross, R., Woodward, O., Lewis, J., Chiarugi, D., Merkle, F., Gribble, F., Reimann, F., & Adriaenssens, A. (2022) · Appetite · doi:10.1016/j.appet.2022.106022 · Cited by 47
The neurobiology of overeating
Stuber, G. D., Schwitzgebel, V., & Lüscher, C. (2025) · Neuron · doi:10.1016/j.neuron.2025.03.010 · Cited by 75
Mansur, R. B., Lee, Y., Subramaniapillai, M., Brietzke, E., & McIntyre, R. S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.048 · Cited by 47
An overview of energy and metabolic regulation
Wen, S., Wang, C., Gong, M., & Zhou, L. (2018) · Science China Life Sciences · doi:10.1007/s11427-018-9371-4 · Cited by 55
Ng, N. B. H., Low, Y. W., Rajgor, D. D., Low, J. M., Lim, Y. Y., Loke, K. Y., & Lee, Y. S. (2021) · Clinical Endocrinology · doi:10.1111/cen.14583 · Cited by 53
“In fact, liraglutide has been shown to induce weight loss through its action on the pro‐opiomelanocortin and cocaine‐ and amphetamine‐regulated transcript (POMC/CART) neurones in the arcuate nucleus, which is the main appetite regulation centre in the hypothalamus.(14) While the role of GLP‐1 in the pathophysiology of…”
BackgroundNonogaki, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031600 · Cited by 53
“Recent studies using liraglutide, a GLP-1R agonist, suggested that GLP-1Rs in the ARC of the hypothalamus contribute to feeding regulation in rats [48].”
BackgroundLe, T. D. V., Fathi, P. A., Watters, A. B., Ellis, B. J., Besing, G.-L. K., Bozadjieva-Kramer, N., Perez, M. B., Sullivan, A. I., Rose, J. P., Baggio, L. L., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101718 · Cited by 50
Pepe, R. B., Lottenberg, A. M., Fujiwara, C. T. H., Beyruti, M., Cintra, D. E., Machado, R. M., Rodrigues, A., Jensen, N. S. O., Caldas, A. P. S., Fernandes, A. E., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01037-6 · Cited by 72
Katsurada, K., Nakata, M., Saito, T., Zhang, B., Maejima, Y., Nandi, S. S., Sharma, N. M., Patel, K. P., Kario, K., & Yada, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-49364-x · Cited by 46
The role of GLP-1 receptor agonists in managing type 2 diabetes
Nachawi, N., Rao, P. P., & Makin, V. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21110 · Cited by 45
“28,29 32 These hypothalamic effects are thought to vary among patients treated with GLP-1 receptor agonists.”
BackgroundGLP-1R Activation by Liraglutide Promotes Breast Cancer Through NOX4/ROS/VEGF Pathway
Liu, Z., Duan, X., Yuan, M., Yu, J. Y., Hu, X., Han, X., Lan, L., Liu, B., Wang, Y., & Qin, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2022.120370 · Cited by 55
Semaglutide seems to be more effective the other GLP-1Ras
Holst, J. J., & Madsbad, S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.10 · Cited by 45
“These receptors are probably reached by the agonists in their free, non-protein bound form via leaks in the blood brain barrier, particularly the area postrema, the subfornical organ and the median eminence (33).”
BackgroundHeppner, K. M., Marks, S., Holland, J., Ottaway, N., Smiley, D., Dimarchi, R., & Perez-Tilve, D. (2015) · Diabetologia · doi:10.1007/s00125-015-3651-3 · Cited by 44
“Importantly, Beiroa et al gave intranuclear brain injections of liraglutide to rats and demonstrate that the VMH, not the ARC, is the site of GLP-1R-mediated activation of BAT [4].”
InfluentialGLP-1 and the Neurobiology of Eating Control: Recent Advances
Jones, L. A., & Brierley, D. I. (2025) · Endocrinology · doi:10.1210/endocr/bqae167 · Cited by 43
Wismann, P., Pedersen, S. L., Hansen, G., Mannerstedt, K., Pedersen, P. J., Jeppesen, P. B., Vrang, N., Fosgerau, K., & Jelsing, J. (2018) · Physiology & Behavior · doi:10.1016/j.physbeh.2018.03.004 · Cited by 43
Self-citationIepsen, E. W., Have, C. T., Veedfald, S., Madsbad, S., Holst, J. J., Grarup, N., Pedersen, O., Brandslund, I., Holm, J.-C., Hansen, T., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100006 · Cited by 43
“However, it was also suggested that liraglutide may act through a local gamma-aminobutyric acid (GABA) neuron, inhibiting the orexigenic agouti-related peptide (AgRP)/neuropeptide Y (NPY) neurons.(10) The importance of the MC4R in appetite and thus body weight regulation is evident by the obese phenotype of the MC4R /…”
BackgroundInfluentialYassine, H. N., Solomon, V., Thakral, A., Sheikh‐Bahaei, N., Chui, H. C., Braskie, M. N., Schneider, L. S., & Talbot, K. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12474 · Cited by 43
Liraglutide: A Review of Its Use in the Management of Obesity
Scott, L. J. (2015) · Drugs · doi:10.1007/s40265-015-0408-8 · Cited by 48
“Evidence from animal studies suggests that weight lowering effects of liraglutide are primarily mediated through central effects, specifically via GLP-1 receptors on arcuate nucleus neurons expressing propiomelanocortin (POMC)/cocaineand amphetamine-regulated transcript (CART) [16].”
BackgroundGPR40 reduces food intake and body weight through GLP-1
Gorski, J. N., Pachanski, M. J., Mane, J., Plummer, C. W., Souza, S., Thomas-Fowlkes, B. S., Ogawa, A. M., Weinglass, A. B., Salvo, J. D., Cheewatrakoolpong, B., et al. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00435.2016 · Cited by 45
“peripheral actions of GLP-1 on body weight, GLP-1 is believed to regulate food intake at least in part through delayed gastric emptying (26, 27).”
BackgroundTrotta, M., Bello, E. P., Alsina, R., Tavella, M. B., Ferrán, J. L., Rubinstein, M., & Bumaschny, V. F. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.100985 · Cited by 47
A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
Tilinca, M. C., Tiuca, R. A., Burlacu, A., & Varga, A. (2021) · Medicina · doi:10.3390/medicina57070669 · Cited by 43
“For example, in the arcuate nucleus, liraglutide stimulates the appetite-inhibiting pro-opiomelanocortin neurons and inhibits the orexigenic neuropeptide-Y and Agouti-related peptide neurons, resulting in reduced food intake and increased satiety [40].”
BackgroundZhu, E., Yang, Y., Zhang, J., Li, Y., Li, C., Chen, L., & Sun, B. (2016) · Oncotarget · doi:10.18632/oncotarget.13189 · Cited by 42
Acquired hypothalamic obesity: A clinical overview and update
Roth, C. L., & McCormack, S. E. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15530 · Cited by 42
Abdelmalek, M. F., Harrison, S. A., & Sanyal, A. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15524 · Cited by 48
Ahmed, I. A. B. (2024) · Journal of Obesity · doi:10.1155/2024/8056440 · Cited by 53
“As the information provided by these studies shows the pathways involved, the withdrawal of GLP-1RA could have a deregulation efect on the CNS in controlling food intake and thus reversing weight gain [50].”
BackgroundInfluentialPharmacotherapy for the treatment of obesity
Sweeting, A., HOCKING, S. L., & Markovic, T. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.005 · Cited by 55
Péterfi, Z., Szilvásy-Szabó, A., Farkas, E., Ruska, Y., Pyke, C., Knudsen, L. B., & Fekete, C. (2021) · Neuroendocrinology · doi:10.1159/000512806 · Cited by 42
Self-citationPark, J. S., Kim, K. S., & Choi, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0106 · Cited by 60
“However, other studies have indicated that POMC GLP-1R knockdown can increase HFD-induced weight gain, and ARC GLP-1R blockade by GLP-1R antagonists attenuated the anorexic effects of liraglutide [57].”
InfluentialMadsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“The mechanism by which GLP-1 exerts its anorectic effects involves both peripheral and brain GLP-1 receptors [14,15].”
Metadata
- Authors
- Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., Schäffer, L., Tang-Christensen, M., Verma, S., Witgen, B. M., Vrang, N., & Bjerre Knudsen, L.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Gubra (Denmark) (DK)
- Oregon National Primate Research Center (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-09-09
- Volume
- 124
- Issue
- 10
- Pages
- 4473-4488
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4215190
- OpenAlex
- W2014156217
- Cited by
- 961
- References
- 95
- Citations by year
- 2026: 100 · 2025: 126 · 2024: 123 · 2023: 85 · 2022: 77 · 2021: 93 · 2020: 56 · 2019: 63 · 2018: 62 · 2017: 65 · 2016: 52 · 2015: 53 · 2014: 5
- FWCI
- 28.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, GLP-1 receptor, arcuate nucleus, weight loss, hypothalamus, proopiomelanocortin neurons, neuropeptide Y, agouti-related protein, GABAergic inhibition, circumventricular organs, GLP-1 analogues, appetite regulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Cocaine- and Amphetamine-Regulated Transcript Protein, Animals, Arcuate Nucleus of Hypothalamus, Body Weight, Disease Models, Animal, Electrophysiology, Hypothalamus, Male, Mice, Transgenic, Nerve Tissue Proteins, Neurons, Paraventricular Hypothalamic Nucleus, Pro-Opiomelanocortin, Vagus Nerve, Weight Loss, Rats, Sprague-Dawley, Receptors, Glucagon, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.